A Major Danish Challenge to Long-Held Vaccine Research Claims

A group of Danish researchers has published a systematic review questioning decades of work by Peter Aaby and Christine Stabell Benn, two prominent scientists who have argued that certain vaccines—particularly measles and tuberculosis vaccines—protect children better than scientists typically believed. The new analysis, led by Henrik Støvring from Steno Diabetes Center Aarhus, is the first comprehensive look at all the randomized trials (controlled studies where participants are randomly assigned to groups) that Aaby and Benn have conducted over roughly 30 years.

Aaby trained as an anthropologist, while Benn is a professor of global health. Together they have run the Bandim Health Project in Guinea-Bissau, a West African country, since the late 1970s. Their core claim is that measles and tuberculosis vaccines do more than just protect against those specific diseases—they argue the vaccines also strengthen the immune system in broader ways, improving a child's overall survival odds. That idea, called non-specific vaccine effects, is legitimate in theory but hard to prove in practice.

The Research Team and Their Hypothesis

Aaby set up the Bandim Health Project in Guinea-Bissau in 1978, and Benn joined in 1993. Over the decades, they have run randomized trials involving thousands of children in both Guinea-Bissau and Denmark. They have also published widely through an organization called the Research Centre for Vitamins and Vaccines (CVIVA).

Wired reported that Aaby and Benn's research tests whether vaccines like measles and BCG (tuberculosis vaccine) improve child health in ways beyond protecting against their target diseases. Benn's work also includes studies on vitamin A supplements and other health interventions. According to ResearchGate, Aaby has published over 220 research papers that have been cited thousands of times, and Benn has extended their research to Denmark and other high-income countries to test whether these same effects appear in wealthier settings.

The New Critique

Aarhus University reported that Støvring's analysis found that Aaby and Benn interpreted their data in ways that were too optimistic about finding non-specific vaccine effects. In other words, when the evidence was ambiguous, they tended to conclude that vaccines had helped—rather than concluding that the data were inconclusive.

This kind of disagreement is not unusual in medical research. The pattern I have seen throughout my career—from debates over HIV treatments in the 1990s to arguments about COVID-19 vaccine data more recently—tends to look like this: researchers working in difficult field conditions, where strict laboratory control is hard to achieve, develop ideas about how their interventions work. Years later, independent teams re-examine the original data using systematic methods and reach different conclusions. What matters is how the scientific community responds and learns.

The Challenge of Non-Specific Effects

The broader picture here is that non-specific vaccine effects are a real immunological phenomenon. Vaccines can influence how the immune system responds beyond their primary target. The measles vaccine, for instance, does more than prevent measles; it can have wider immune effects. The difficult part is measuring those side effects reliably in real-world conditions where many things are happening at once—children eating different diets, exposed to different diseases, living in changing health systems.

Aaby and Benn's work in Guinea-Bissau has spanned over 40 years, giving them long-term data that few other researchers can match. But that same long timeframe also means the health environment changed many times over—new diseases emerged, healthcare improved, poverty patterns shifted. Isolating the vaccine's effect from all those other changes is genuinely hard.

Methodological Pressures and Patterns

The Støvring analysis points to a broader question: when researchers work with vulnerable populations in poor settings and genuinely want to help, how do they balance urgency with scientific caution. If a vaccine seems to be working, the ethical pressure to recommend it immediately can be intense. But moving too fast without ironclad evidence can also harm people if the vaccine turns out to have unexpected downsides or the effect doesn't hold up in other contexts.

The fact that Støvring identified a systematic pattern—not just isolated problems in one or two studies, but a consistent tendency across Aaby and Benn's entire body of work—suggests this goes beyond the usual noise of individual research mistakes. It raises real questions about how the peer review system worked, how often the original findings were challenged, and what institutional pressures might have shaped the research.

What Comes Next

The research community now has to figure out what to believe about three decades of published work when a careful systematic review says the original conclusions were too strong. This will likely involve independent researchers trying to replicate the findings, refining the methods used, and possibly changing recommendations for health programs that were based on Aaby and Benn's original research.

For people working in global health, the lesson is clear: robust evidence standards matter before scaling up an intervention to reach millions of children. The tools for doing systematic reviews and checking for patterns across many studies have become much faster and more accessible than they were when Aaby and Benn started their work in the 1970s.

The bigger story is about how research institutions can balance the genuine urgency of helping people in poor countries with the scientific rigor needed to know whether an intervention actually works. Better methods, stronger peer review, and clearer standards about when conclusions are solid versus provisional—those things will likely shape how this kind of research gets done going forward.